Respiri's $3 million placement to accelerate US commercialisation strategy

Respiri Limited (ASX: $RSH) has successfully raised $3 million through a placement to sophisticated and professional investors. The placement involves issuing 100,000,000 new fully paid ordinary shares at an issue price of $0.03 per share, representing a 3.4% premium to the company's last closing price. This funding is intended to support the accelerated execution of the company's US commercialisation strategy, patient recruitment, and finalization of risk share capitated contracts, with the goal of achieving cashflow breakeven by late 2024.

Executive commentary on funding and strategic opportunities

The company is pleased with the strong market support and endorsement of the strategic opportunities as it continues to pursue the large Remote Patient Monitoring market in the USA.

Summary of Respiri's funding and strategic outlook

Respiri Limited (ASX: $RSH) has successfully secured $3 million through a placement, demonstrating investor confidence in the company's strategy and execution capability. The funding will be utilized to accelerate the execution of the US commercialisation strategy, including patient recruitment, onboarding, and finalizing risk share capitated contracts. This aligns with the company's goal of achieving cashflow breakeven by late 2024. Respiri's strong market support reflects its commitment to pursuing opportunities in the large Remote Patient Monitoring market in the USA, positioning the company for continued growth and impact in transforming healthcare delivery.